Home
Search
Agriculture & Environment

Addressing Climate Change

There are more than 5 trillion pieces of plastic floating in our oceans. The U.S. transportation sector leads all other sectors in greenhouse gas emissions. Diseases that thrive in hot weather are killing important staple crops. Our reliance on products derived from fossil fuels is harming our planet.

Climate change is real but through biotechnology, we can meet these challenges head-on by making the same reliable plastics, foods, and fuels with less environmental impact.

Dr Michelle Climate
Biotech Solutions for Climate Report
Biotech Solutions for Climate Executive Summary
More on BIO's Global Climate Leadership
Latest from BIO's Experts...
GMOS and Gene Editing—Nothing to Be Afraid Of
GMOS and Gene Editing—Nothing to Be Afraid Of
Learn more
Escaping the Food Allergy Prison
Escaping the Food Allergy Prison
Learn more
Car Free Day
Car-Free Day: Could Biotech Make It a Thing of the Past?
Learn more
Bananas
Improving Food Systems: The Case of the Banana
Learn more
roots Trees Alone Can’t Solve Our Climate Issues
Trees Alone Can’t Solve Our Climate Issues
Learn more
Press Releases
Browse all Press Releases
CMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent
January 13, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to restrict coverage for drugs used to treat…
"Build Back Better Act" Drug Pricing Provisions Weaken U.S. Innovation Ecosystem, Hurt Patients
November 19, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build Back Better Act: “The legislation that passed the House today will upend a successful Medicare system and weaken…
Patients Empowered with New “Clinical Trials: The Power of Participation” Website
November 16, 2021
The Biotechnology Innovation Organization (BIO) today announced the launch of Clinical Trials: The Power of Participation (CTPoP), a website that addresses how clinical trials work, how to enroll in a clinical trial, and what to expect as a clinical trial participant with sound, science-based…
Good Day BIO Newsletter
Subscribe to GoodDay BIO

Receive the best resource for the biotech industry with Good Day BIO, the only daily newsletter at the intersection of biotech, politics and policy. 

Subscribe

A Timeline of Modernizing Food and Farm Biotech Laws...

plants
2019: USDA Announces SECURE Rule

To provide transparency to consumers, BIO advocates for the agency to require developers to notify them when new plants are brought to market,
Cabinet
2019: Executive Order to Modernize Biotech Framework

President Trump directs USDA, EPA, and FDA to align existing biotech regulations with actual risk and to grow pubic confidence in biotech to benefit our food, health, and planet.
Trump Rural
2017: Trump Administration Establishes Rural Prosperity Task Force

The task force includes biotechnology as part of its recommendations to the government on how to strengthen rural economies.
Obama produce
2017: Obama Administration Updates Biotech Laws

To keep up with 21st-century innovations USDA and FDA begin updating definitions and enforcement of biotech plants and animals. 
obama flag
2012: National Bioeconomy Blueprint Unveiled

The blueprint is a comprehensive vision to strengthen America's economy through technology and science, and spotlights agricultural biotechnology.
Letters, Comments & Testimony
Browse all Letters, Comments & Testimony
Senate Finance Committee Leadership Sends Letter to USTR Ambassador Tai, Notes Mexico's Failure to Adhere to Biotech Commitments
January 12, 2021
The United States-Mexico-Canda Agreement has the potential to deliver tangible benefits for America's workers, farmers, and businesses by improving and strengthening the relationship between the United States and its two closest trading partners. However, that potential will not be realized without…
BIO Comments on Draft Guidance: Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C
January 3, 2022
On Wednesday, December 29th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act. Existing regulations require each…
BIO Comments on Draft Guidance: Q13 Continuous Manufacturing of Drug Substances and Drug Products
December 13, 2021
On Monday, December 13th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Q13 Continuous Manufacturing of Drug Substances and Drug Products. The draft guidance was prepared under the auspices of the International Council for Harmonisation …